c-FMS

Pexidartinib (PLX3397)is a potent, orally active, selective, and ATP-competitive CSF1R and c-Kit inhibitor, with IC 50 values of 0.02μM and 0.01μM, respectively.

BLZ945 (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.

VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor

A c-Fms kinase inhibitor

Inhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck

dual inhibitor of FMS and KIT kinases

GW2580 is a selective and orally bioavailable inhibitor of colony-stimulating factor-1 receptor (CSF-1R), with an IC 50 of 30nM, and completely inhibits the human c-Fms kinase at 0.06μM.

Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis.

AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity)

Edicotinib is a selective and orally available colony-stimulating factor-1 (CSF-1) receptor inhibitor, and has entered phase IIA clinical trial to study rheumatoid arthritis (RA) despite disease.

GENZ-882706(Raceme) (GENZ-882706 racemate) is the racemate of GENZ-882706.

cFMS-IN-2 is a FMS kinase inhibitor with an IC50 of 0.024 μM.

GENZ-882706 (RA03546849) is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.

An irreversible pan-FGFR inhibitor

CSF1R-IN-1 is a CSF1R inhibitor with an with an IC50 of 0.5 nM.

cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor.

c-Fms-IN-1 is a FMS kinase inhibitor with an IC50 of 0.0008 μM.

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity.

c-Fms-IN-10 is the derivative of thieno [3,2-d] pyrimidine, an kinase inhibitor of FMS (Colony stimulating factor-1 receptor, CSF-1R) with IC50 of 2 nM.

c-Fms-IN-3 is a novel c-Fms kinase inhibitor with a potential as anti-inflammatory agent and antirheumatic agent.

c-Fms-IN-8 (compound 4a) is a colony stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor, with an IC50 of 9.1 nM.

c-Fms-IN-9 is a c-FMS inhibitor extracted from patent WO2014145023A1, Compound Example 7. c-Fms-IN-9 inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT with IC50s of <0.01 μM and 0.1-1 μM, respectively.

PLX5622 is a selective inhibitor of colony-stimulating factor 1 receptor (CSFR1) with an IC 50 value of 0.016μM.

PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor (IC50=0.016 μ M; Ki=5.9 nM).